Celldex Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Celldex Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-09-30 | 2004-06-30 | 2004-03-31 | 2003-09-30 | 2003-06-30 | 2003-03-31 | 2002-09-30 | 2002-03-31 | 2001-09-30 | 2001-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product development and licensing agreements | 2,000 | 273,000 | 2,000 | 16,000 | 37,000 | 30,000 | 1,000 | 26,000 | 3,000 | 2,272,000 | 12,000 | 3,000 | 4,000 | 12,000 | 2,286,000 | 55,000 | 195,000 | 129,000 | 131,000 | 1,667,000 | 992,000 | 1,238,000 | 694,000 | 556,000 | 493,000 | 604,000 | 453,000 | 377,000 | 334,000 | 342,000 | 284,000 | 200,000 | 35,000 | 40,000 | 47,000 | 30,000 | 28,000 | 40,000 | 35,000 | 40,000 | 11,000 | 14,000 | 1,371,000 | 1,399,000 | 1,347 | 1,339,000 | 1,497,000 | 1,501,847 | 1,245,442 | 870,504 | 119,864 | 100,508 | 10,018 | 8,086 | 35,475 | 17,446 | 2,619,974 | 78,692 | 59,060 | 71,457 | 144,300 | 124,400 | 2,124,400 | 1,232,900 | 217,700 | 169,400 | 4,493,900 | 585,300 | 663,800 | 731,600 | |||||||||
| contracts and grants | 2,498,000 | 154,000 | 765,000 | 1,515,000 | 252,000 | 967,000 | -432,000 | 407,000 | 163,000 | 144,000 | 3,906,000 | 153,000 | 3,454,000 | 682,000 | 829,000 | 656,000 | 236,000 | 682,000 | 3,781,000 | 656,000 | 236,000 | 442,000 | 491,000 | 520,000 | 1,296,000 | 810,000 | 1,096,000 | 3,076,000 | 2,686,000 | 3,135,000 | 978,000 | 1,727,000 | 785,000 | 850,000 | 649,000 | 1,844,000 | 144,000 | 817,000 | 392,000 | 381,000 | 940,000 | 50,000 | 50,000 | 79,000 | 96,000 | 54,000 | 5,000 | 220 | 799,000 | 139,343 | 137,685 | 253,985 | |||||||||||||||||||||||||||
| total revenues | 2,498,000 | 156,000 | 1,038,000 | 1,517,000 | 268,000 | 967,000 | -395,000 | 407,000 | 163,000 | 174,000 | 3,907,000 | 153,000 | 3,480,000 | 685,000 | 3,101,000 | 668,000 | 236,000 | 685,000 | 3,785,000 | 668,000 | 236,000 | 2,728,000 | 546,000 | 715,000 | 1,425,000 | 941,000 | 2,763,000 | 4,068,000 | 3,924,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 39,687,000 | 31,661,000 | 1,400,000 | 34,535,000 | 26,252,000 | 26,798,000 | -5,327,000 | 21,572,000 | 20,731,000 | 17,056,000 | -6,048,000 | 13,557,000 | 12,356,000 | 12,720,000 | 3,901,000 | 10,708,000 | 9,705,000 | 12,720,000 | 10,425,000 | 10,708,000 | 9,705,000 | 11,695,000 | 11,101,000 | 10,081,000 | 11,151,000 | 11,918,000 | 21,448,000 | 21,875,000 | 21,915,000 | 24,999,000 | 25,793,000 | 25,009,000 | 25,711,000 | 27,447,000 | 24,656,000 | 26,490,000 | 25,125,000 | 26,185,000 | 24,100,000 | 27,070,000 | 20,417,000 | 15,090,000 | 14,090,000 | 11,769,000 | 11,114,000 | 10,769,000 | 8,594,000 | 7,169,000 | 6,853,000 | 7,215,000 | 7,256,000 | 6,438 | 7,241,000 | 7,802,000 | 8,685,941 | 6,626,059 | 7,611,666 | 4,486,774 | 4,457,475 | 4,967,629 | 4,958,702 | 4,416,320 | 4,463,899 | 4,348,707 | 3,591,334 | 3,430,992 | 4,030,618 | 2,805,800 | 3,367,800 | 3,453,200 | 2,510,100 | 2,673,400 | 2,692,500 | 3,423,200 | 4,409,600 | 5,633,100 | 5,440,500 | ||
| general and administrative | 9,128,000 | 9,103,000 | 2,629,000 | 8,221,000 | 7,221,000 | 6,640,000 | 5,113,000 | 6,531,000 | 7,154,000 | 6,911,000 | -108,000 | 5,821,000 | 4,306,000 | 4,121,000 | 209,000 | 3,640,000 | 3,528,000 | 4,121,000 | 3,623,000 | 3,640,000 | 3,528,000 | 3,666,000 | 3,403,000 | 3,908,000 | 4,896,000 | 3,722,000 | 5,621,000 | 5,593,000 | 5,346,000 | 6,534,000 | 7,229,000 | 6,950,000 | 7,790,000 | 9,307,000 | 8,487,000 | 8,184,000 | 6,089,000 | 5,004,000 | 4,787,000 | 4,582,000 | 3,578,000 | 3,411,000 | 3,138,000 | 2,835,000 | 2,219,000 | 2,317,000 | 2,273,000 | 2,240,000 | 2,386,000 | 2,421,000 | 2,591,000 | 2,835 | 3,850,000 | 3,511,000 | 3,341,253 | 4,206,081 | 4,605,482 | 3,032,758 | 2,000,271 | 1,671,138 | 2,051,977 | 1,818,799 | 2,117,192 | 1,988,514 | 1,670,306 | 1,861,095 | 1,710,784 | 1,290,600 | 1,269,700 | 1,292,100 | |||||||||
| total operating expenses | 48,815,000 | 40,764,000 | 16,529,000 | 42,756,000 | 33,473,000 | 33,438,000 | 7,924,000 | 28,103,000 | 36,559,000 | 23,431,000 | -12,199,000 | 20,977,000 | 16,920,000 | 17,324,000 | 15,552,000 | 15,010,000 | 11,601,000 | 17,324,000 | 28,566,000 | 15,010,000 | 11,601,000 | 15,595,000 | 12,390,000 | 12,972,000 | 19,366,000 | 8,705,000 | 19,636,000 | 123,745,000 | 35,885,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| operating income | -46,317,000 | -40,608,000 | -15,491,000 | -41,239,000 | -33,205,000 | -32,471,000 | -8,319,000 | -27,696,000 | -36,396,000 | -23,257,000 | 16,106,000 | -20,824,000 | -13,440,000 | -16,639,000 | -12,451,000 | -14,342,000 | -11,365,000 | -16,639,000 | -24,781,000 | -14,342,000 | -12,867,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| yoy | 39.49% | 25.06% | 86.21% | 48.90% | -8.77% | 39.62% | -151.65% | 33.00% | 170.80% | 39.77% | -229.36% | 45.20% | 18.26% | 0.00% | -49.76% | 0.00% | 29.32% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| qoq | 14.06% | 162.14% | -62.44% | 24.20% | 2.26% | 290.32% | -69.96% | -23.90% | 56.49% | -244.40% | -177.34% | 54.94% | -19.23% | 33.64% | -13.19% | 26.19% | -31.70% | -32.86% | 72.79% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating margin % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment and other income | 10,475,000 | 7,800,000 | -15,167,000 | 2,979,000 | 2,703,000 | 3,110,000 | -5,883,000 | 912,000 | 392,000 | 207,000 | -1,006,000 | 145,000 | 67,000 | 101,000 | 2,094,000 | 118,000 | 106,000 | 101,000 | 1,942,000 | 118,000 | 106,000 | 242,000 | 431,000 | 478,000 | 702,000 | 521,000 | 466,000 | 780,000 | 398,000 | 362,000 | 851,000 | 395,000 | 414,000 | 1,031,000 | 391,000 | 391,000 | 807,000 | 2,260,000 | 275,000 | 1,586,000 | 142,000 | 161,000 | 379,000 | 105,000 | 126,000 | 205,000 | 144,000 | 79,000 | 84,000 | 124,000 | 95,000 | 3,162 | 18,000 | 82,487 | 921,820 | 99,191 | 46,254 | 132,778 | 364,173 | 442,251 | 624,331 | 654,091 | 280,521 | 149,662 | 169,764 | 151,129 | 120,400 | ||||||||||||
| net income | -35,842,000 | -32,808,000 | -30,658,000 | -38,260,000 | -30,502,000 | -29,361,000 | -14,202,000 | -26,784,000 | -36,004,000 | -23,050,000 | 15,327,000 | -20,452,000 | -13,373,000 | -16,538,000 | -9,417,000 | -14,224,000 | -11,031,000 | -16,538,000 | -21,900,000 | -14,224,000 | -12,625,000 | -11,413,000 | -11,779,000 | -17,239,000 | -7,243,000 | -16,407,000 | -118,132,000 | -26,363,000 | -28,566,000 | -34,261,000 | -29,598,000 | -31,952,000 | -34,673,000 | -31,980,000 | -32,359,000 | -30,174,000 | -28,082,000 | -28,274,000 | -29,903,000 | -23,140,000 | -19,016,000 | -17,332,000 | -15,027,000 | -13,773,000 | -13,516,000 | -11,772,000 | -10,236,000 | -10,059,000 | -9,087,000 | -9,525,000 | -6,582 | -7,174,000 | -8,705,000 | -7,703,877 | -7,656,158 | -10,260,510 | -22,130,682 | -5,505,246 | -5,626,279 | -5,520,567 | -5,670,299 | -2,970,991 | -4,514,434 | -4,733,940 | -4,868,499 | -3,697,200 | -3,898,800 | -1,909,400 | -2,115,700 | -3,183,300 | -3,362,200 | -276,200 | -4,913,600 | -6,224,000 | -5,660,300 | ||||
| yoy | 17.51% | 11.74% | 115.87% | 42.85% | -15.28% | 27.38% | -192.66% | 30.96% | 169.23% | 39.38% | -262.76% | 43.79% | 21.23% | 0.00% | -57.00% | 0.00% | 30.99% | 91.89% | 20.76% | 74.31% | -30.44% | -90.03% | -34.61% | -74.64% | -52.11% | 299.12% | -17.49% | -17.61% | 7.13% | -8.53% | 5.89% | 23.47% | 13.11% | 8.21% | 30.40% | 47.68% | 63.13% | 99.00% | 68.01% | 40.69% | 47.23% | 46.81% | 36.92% | 48.74% | 23.59% | 155415.04% | 40.21% | 4.39% | 23.64% | -99.91% | -30.08% | -60.67% | 39.07% | 82.37% | -2.91% | 89.37% | 22.29% | 19.78% | -38.98% | 15.79% | 147.93% | 130.11% | 16.14% | 15.96% | 591.31% | -56.94% | -48.85% | -40.60% | |||||||||||
| qoq | 9.25% | 7.01% | -19.87% | 25.43% | 3.89% | 106.74% | -46.98% | -25.61% | 56.20% | -250.39% | -174.94% | 52.94% | -19.14% | 75.62% | -33.79% | 28.95% | -33.30% | -24.48% | 53.97% | 10.62% | -3.11% | -31.67% | 138.01% | -55.85% | -86.11% | 348.10% | -7.71% | -16.62% | 15.75% | -7.37% | -7.85% | 8.42% | -1.17% | 7.24% | 7.45% | -0.68% | -5.45% | 29.23% | 21.69% | 9.72% | 15.34% | 9.10% | 1.90% | 14.81% | 15.01% | 1.76% | 10.70% | -4.60% | 144612.85% | -99.91% | -17.59% | 13.00% | 0.62% | -25.38% | -53.64% | -2.15% | -2.64% | 90.86% | -4.64% | -2.76% | 31.68% | -5.17% | 104.19% | -9.75% | -33.54% | -5.32% | 1117.31% | -94.38% | -21.05% | 9.96% | |||||||||
| net income margin % | -746.04% | -2233.44% | -1333.24% | -2300.36% | -2661.01% | -3116.96% | -1485.72% | -6208.64% | -2550.59% | -4776.01% | -7188.22% | -2361.22% | -19604.12% | -717.98% | -482.72% | -685.56% | -555.53% | -498.18% | -524.39% | -399.80% | -377.37% | -322.77% | -177.27% | -178.01% | -324.21% | -206.45% | -324.67% | -523.07% | -15014.23% | -545.40% | -475.92% | -1628.49% | -1121.77% | -80.16% | -533.42% | -742.97% | -501.62% | -700.76% | -436.60% | -63.00% | -104.99% | -295.19% | -493.21% | -6.06% | -711.19% | -857.89% | -685.43% | ||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -540 | -560 | -435 | -810 | -650 | -620 | -520 | -570 | -770 | -490 | -457.5 | -450 | -340 | -420 | -302.5 | -360 | -500 | -420 | -360 | -360 | -730 | -750 | -840 | -1,400 | -40 | -110 | -840 | -200 | -230 | -280 | -290 | -320 | -350 | -320 | -330 | -330 | -310 | -320 | -330 | -290 | -240 | -230 | -250 | -230 | -270 | -270 | -270 | -310 | -280 | -300 | -0.21 | -450 | -550 | -0.49 | -0.49 | -0.67 | -2.19 | -0.07 | -0.07 | -0.07 | -0.07 | -0.08 | -0.04 | -0.06 | -0.06 | -0.07 | -0.05 | -0.05 | -0.03 | -0.03 | -0.05 | -0.06 | -0.01 | -0.08 | -0.11 | -0.1 | |||
| shares used in calculating basic and diluted net income per share | 66,019 | 58,871 | 15,934.25 | 47,261 | 47,253 | 47,214 | 11,810.75 | 46,916 | 46,759 | 46,739 | 11,701.5 | 45,453 | 39,616 | 39,614 | 10,395.5 | 39,278 | 22,082 | 39,614 | 6,575.75 | 39,278 | 22,082 | 17,406 | 15,282 | 13,952 | 12,297 | 163,679 | 147,428 | 140,548 | 129,640 | 125,202 | 122,648 | 100,672 | 98,817 | 98,689 | 98,568 | 98,482 | 92,437 | 89,404 | 89,361 | 89,270 | 81,015 | 80,899 | 74,027 | 59,467 | 58,733 | 50,145 | 44,136 | 37,463 | 32,047 | 31,922 | 31,815 | 31,695 | 15,879 | 15,834 | 15,818,946 | 15,708,244 | 15,227,475 | 10,127,435 | 75,188,022 | 75,184,048 | |||||||||||||||||||
| comprehensive loss: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | -464 | -1,064 | 495 | 63 | -51 | 863 | 218.75 | 305 | -529 | -1,782 | -501.5 | -44 | 5 | -10.25 | 14 | -3 | -2.75 | 14 | -22 | 36 | 19 | 31 | 11 | 15 | 21 | 36 | 380 | 124 | 11 | 80 | 1 | 138 | 52 | 108 | |||||||||||||||||||||||||||||||||||||||||||||
| comprehensive loss | -36,306 | -33,872 | -27,197.75 | -38,197 | -30,553 | -28,498 | -24,312 | -26,479 | -36,533 | -24,832 | -21,961 | -20,496 | -13,368 | -16,540 | -12,601 | -14,210 | -11,034 | -16,540 | -9,472.75 | -14,210 | -12,647 | -11,416 | -11,743 | -17,220 | -7,251 | -16,376 | -118,137 | -26,352 | -28,551 | -34,240 | -29,711 | -31,916 | -34,293 | -31,856 | -32,539 | -30,148 | -28,206 | -28,196 | -29,901 | -23,002 | -19,157 | -17,388 | -14,974 | -13,813 | -13,406 | -7,649,724 | -10,413,386 | -22,241,512 | |||||||||||||||||||||||||||||||
| gain on fair value remeasurement of contingent consideration | -6,326,000 | -536,000 | 5,457,000 | -1,901,000 | -5,132,000 | 18,000 | 662,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| litigation settlement related loss | 15,000,000 | 3,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| intangible asset impairment | 3,500,000 | 14,500,000 | 3,500,000 | 14,500,000 | 3,500,000 | 18,677,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before income tax benefit | 15,100,000 | -20,679,000 | -10,357,000 | -14,224,000 | -11,259,000 | -22,839,000 | -14,224,000 | -118,897,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 227,000 | 940,000 | 228,000 | 939,000 | 228,000 | 765,000 | 5,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (gain) loss on fair value remeasurement of contingent consideration | 258,000 | 483,000 | -290,000 | 662,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on marketable securities | -2 | -2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on fair value remeasurement of contingent consideration | 483,000 | 234,000 | 1,000,000 | 3,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other asset impairment | 1,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| goodwill impairment | 90,976,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of acquired intangible assets | 224,000 | 224,000 | 224,000 | 224,000 | 254,000 | 254,000 | 253,000 | 254,000 | 254,000 | 253,000 | 254,000 | 254,000 | 253,000 | 254,000 | 254,000 | 253,000 | 254,000 | 291,000 | 291,000 | 656,000 | 483,000 | 483,000 | 483,000 | 658,000 | 1,520 | 95,000 | 95,000 | 95,309 | 103,974 | 104,164 | 48,894 | 240,048 | 240,048 | 240,048 | 248,778 | 248,778 | 248,778 | 248,778 | 248,778 | 248,778 | 248,800 | 248,800 | 248,800 | 248,800 | 248,800 | 198,800 | 198,800 | 344,000 | 344,000 | ||||||||||||||||||||||||||||||
| other comprehensive income | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (gain)/loss on fair value remeasurement of contingent consideration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss/(gain) on fair value remeasurement of contingent consideration | 1,519,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| in-process research and development impairment | 13,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 3,829,000 | 1,534,000 | 2,220,000 | 1,389,000 | 1,303,000 | 1,026,000 | 2,178,000 | 486,000 | 1,101,000 | 592,000 | 416,000 | 980,000 | 97,000 | 2,414,000 | 3,113,000 | 2,009,000 | 2,433,000 | 2,363,000 | 1,952,000 | 2,516,000 | 2,408,000 | 2,951,000 | 3,713 | 4,030,000 | 2,685,000 | 3,731,647 | 2,358,136 | 1,961,611 | 147,398 | 1,191,535 | 1,009,396 | 1,182,197 | 338,999 | 505,479 | 3,706,487 | 846,322 | 637,161 | 970,552 | 527,600 | 893,000 | 3,030,700 | 2,015,100 | 1,078,400 | 681,700 | 4,560,400 | 690,900 | 725,500 | 825,800 | |||||||||||||||||||||||||||||||
| yoy | 193.86% | 49.51% | 1.93% | 185.80% | 18.35% | 73.31% | 423.56% | -50.41% | 1035.05% | -75.48% | -86.64% | -51.22% | -96.01% | 2.16% | 59.48% | -20.15% | 1.04% | -19.93% | 52472.04% | -37.57% | -10.32% | -20.92% | -99.84% | 105.44% | 1721.60% | 213.18% | 133.62% | 65.93% | 251.49% | 99.69% | -68.10% | -59.94% | -20.67% | 281.89% | -5.23% | -78.98% | -51.84% | -51.08% | 31.00% | -33.54% | 191.66% | 48.64% | -17.45% | ||||||||||||||||||||||||||||||||||||
| qoq | 149.61% | -30.90% | 59.83% | 6.60% | 27.00% | -52.89% | 348.15% | -55.86% | 85.98% | 42.31% | -57.55% | 910.31% | -95.98% | -22.45% | 54.95% | -17.43% | 2.96% | 21.06% | -22.42% | 4.49% | -18.40% | 79377.51% | -99.91% | 50.09% | -28.05% | 58.25% | 20.21% | 1230.83% | -87.63% | 18.04% | -14.62% | -32.94% | -86.36% | 32.83% | -34.35% | 83.96% | -40.92% | -70.53% | 50.40% | 86.86% | 58.19% | -85.05% | 560.07% | -4.77% | -12.15% | ||||||||||||||||||||||||||||||||||
| operating expense: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expense | 32,757,000 | 36,646,000 | 32,213,000 | 33,755,000 | 37,007,000 | 33,397,000 | 34,928,000 | 31,467,000 | 31,443,000 | 29,141,000 | 31,905,000 | 24,249,000 | 18,755,000 | 19,815,000 | 17,864,000 | 15,497,000 | 15,721,000 | 13,841,000 | 11,833,000 | 12,174,000 | 11,287,000 | 12,237,000 | 13,120 | 11,186,000 | 11,408,000 | 11,518,011 | 10,936,114 | 12,321,312 | 22,324,334 | 6,697,794 | 6,878,815 | 7,250,727 | 6,483,897 | 6,829,869 | 6,585,999 | 5,510,418 | 5,540,865 | 5,990,180 | 4,345,200 | 4,886,300 | 4,994,100 | 4,182,600 | 4,273,900 | 4,166,000 | 4,957,900 | 5,808,000 | 7,307,200 | 6,980,900 | |||||||||||||||||||||||||||||||
| foreign currency translation adjustments | 15 | 1 | 1 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product royalties | 2,334,000 | 3,006,000 | 1,873,000 | 2,344,000 | 2,318,000 | 1,941,000 | 2,502,000 | 1,037,000 | 1,552,000 | 2,146 | 1,892,000 | 1,188,000 | 2,090,457 | 975,009 | 837,122 | 1,000,878 | 910,379 | 911,852 | 23,105 | 27,510 | 586,306 | 55,138 | 33,008 | 49,100 | 53,900 | 26,400 | 48,500 | 42,100 | 35,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| royalty | 2,334,000 | 3,006,000 | 1,873,000 | 2,344,000 | 2,318,000 | 1,941,000 | 2,502,000 | 1,218,000 | 1,732,000 | 2,327 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| charge for in-process research and development | 14,755,908 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain / (loss) on foreign exchange translation | 6,434 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain / (loss) on investment in select vaccines ltd. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| government contracts and grants | 27,534 | 90,149 | 88,999 | 262,259 | 280,419 | 460,523 | 500,207 | 767,630 | 522,963 | 866,087 | 334,200 | 714,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized losses on foreign exchange translation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized losses on investment in select vaccines ltd. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit from income taxes | -5,373,481 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | 372,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in calculating basic and diluted earnings per share | 75,183,981 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding | 74,182,347 | 74,174,761 | 74,172,563 | 74,143,000 | 74,145,814 | 74,132,829 | 74,131,999 | 74,118,300 | 74,091,600 | 69,169,600 | 64,703,000 | 60,468,700 | 60,468,600 | 60,464,900 | 60,457,400 | 57,379,700 | 57,355,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment income | 94,500 | 54,000 | 51,800 | 12,200 | 122,100 | 121,300 | 203,500 | 357,700 | 494,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| government contracts | 879,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of intangible assets | 248,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| government contract revenue | 733,700 | 818,600 | 477,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product sales | 66,500 | 105,600 | 61,700 | 94,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 1,423,700 | 1,351,700 | 1,224,700 | 1,325,600 | 1,185,900 | 1,321,700 | 1,188,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of product sales | 10,300 | 13,700 | 8,400 | 8,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of goodwill |
We provide you with 20 years income statements for Celldex Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Celldex Therapeutics stock. Explore the full financial landscape of Celldex Therapeutics stock with our expertly curated income statements.
The information provided in this report about Celldex Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.